DBV Technologies S.A. American Depositary Shares (DBVT)
Stock · NASDAQ · Health Care
$9.05as of 10/16/2026
Price chart
Active signals
DBVT Signal Track Record
How signals performed across all stocks →What DBVT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume SpikeActive now | 52 | -6.4% | 31% | September 28, 2026 |
| Bollinger Band Breakdown | 21 | -4.8% | 43% | October 2, 2026 |
| Bollinger Band Breakout | 23 | -6.3% | 43% | August 17, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -7.2% | 25% | June 12, 2026 |
| Any 20-session window (baseline) | -4.9% | 37% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DBVT
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 170
- Website
- www.dbv-technologies.com/
Fundamentals
- 1-day range
- $8.63$9.13
- Market cap
- $813.58M
- P/E (trailing)
- —
- P/E (forward)
- -18.63
- EPS (trailing)
- $-1.07
- Dividend yield
- —
- Beta
- -0.17
- Avg. volume
- 350.3K
How DBV Technologies S.A. American Depositary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
DBV Technologies S.A. American Depositary Shares Competitors
Chosen by industry and closest market cap.
- DBVTDBV Technologies S.A. American Depositary Shares$9.05▼ 0.66%Market cap $813.58MP/E —$1.57$4.5
- AURAAura Biosciences Inc. Common Stock$6.1▼ 3.79%Market cap $798.53MP/E —$4.73$9.54
- CADLCandel Therapeutics Inc. Common Stock$8.19▼ 8.08%Market cap $775.20MP/E —$4.35$14
- SLDBSolid Biosciences Inc. Common Stock$5.53▼ 3.66%Market cap $857.50MP/E —$3.79$11.45
- ATTOAttovia Therapeutics Inc. Common Stock$13.73▼ 7.10%Market cap $928.90MP/E 0.00$14.23$28
- ALLOAllogene Therapeutics Inc. Common Stock$1.31▼ 2.24%Market cap $679.95MP/E —$1.04$4.46
- SANASana Biotechnology Inc. Common Stock$2.27▼ 8.28%Market cap $948.97MP/E —$2.32$6.55
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DBVT DBV Technologies S.A. American Depositary Shares | $813.58M | — | $9.05 | ▼ 0.66% | $1.57$4.5 |
| AURA Aura Biosciences Inc. Common Stock | $798.53M | — | $6.1 | ▼ 3.79% | $4.73$9.54 |
| CADL Candel Therapeutics Inc. Common Stock | $775.20M | — | $8.19 | ▼ 8.08% | $4.35$14 |
| SLDB Solid Biosciences Inc. Common Stock | $857.50M | — | $5.53 | ▼ 3.66% | $3.79$11.45 |
| ATTO Attovia Therapeutics Inc. Common Stock | $928.90M | 0.00 | $13.73 | ▼ 7.10% | $14.23$28 |
| ALLO Allogene Therapeutics Inc. Common Stock | $679.95M | — | $1.31 | ▼ 2.24% | $1.04$4.46 |
| SANA Sana Biotechnology Inc. Common Stock | $948.97M | — | $2.27 | ▼ 8.28% | $2.32$6.55 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- European Equities Traded in the US as American Depositary Receipts Track Higher in Friday TradingYahoo · 10/2/2026
- European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday TradingYahoo · 10/1/2026
- European Equities Traded in the US as American Depositary Receipts Decline in Wednesday TradingYahoo · 9/30/2026
- Reported Earlier, DBV Technologies Submits BLA To FDA For VIASKIN Peanut Patch In Children Aged 4-7 With Peanut Allergy, Requests Priority ReviewBenzinga · 9/30/2026
- DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 YearsYahoo · 9/29/2026
- European Equities Traded in the US as American Depositary Receipts Edge Lower in Thursday TradingYahoo · 9/24/2026
- European Equities Traded in the US as American Depositary Receipts Fall in Wednesday TradingYahoo · 9/23/2026
- European Equities Traded in the US as American Depositary Receipts Drop in Friday TradingYahoo · 9/18/2026
Insider Activity
Insider Actions →- Pharis Mohideen · July 29, 2026 · Sale464 @ $2.7
Institutional Ownership
March 31, 2026
- Total shares held
- 21.17M
- Total value held
- $424.99M
- Institutional holders
- 70
- Unknown5.21M
- Unknown2.67M
- Unknown2.22M
- Unknown1.86M
- Unknown1.46M
- Unknown1.01M
- Unknown964.4K
- Unknown693.5K
- Unknown574.2K
- Unknown525.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
DBVT ADRs See Minor Gains as European ADRs Rise
The group of European stocks traded as ADRs in the U.S. edged up on Tuesday and opened higher on Monday. DBVT, an ADR of DBV Technologies, was part of that group and saw a modest lift in its price. The move reflects broader market sentiment for European ADRs rather than a company‑specific event.
DBVT ADRs See Minor Gains as European ADRs Rise. The group of European stocks traded as ADRs in the U.S. edged up on Tuesday and opened higher on Monday. DBVT, an ADR of DBV Technologies, was part of that group and saw a modest lift in its price. The move reflects broader market sentiment for European ADRs rather than a company‑specific event.